FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP‐activated protein kinase–Caspase 6 signal axis
Lintao Song,Luyao Wang,Yushu Hou,Jie Zhou,Chuchu Chen,Xianxi Ye,Wenliya Dong,Huan Gao,Yi Liu,Guanting Qiao,Tongtong Pan,Qiong Chen,Yu Cao,Fengjiao Hu,Zhiheng Rao,Yajing Chen,Yu Han,Minghua Zheng,Yongde Luo,Xiaokun Li,Yongping Chen,Zhifeng Huang
DOI: https://doi.org/10.1002/hep.32404
IF: 17.298
2022-02-27
Hepatology
Abstract:Non-alcoholic fatty liver disease (NAFLD) represents an increasing health problem in association with obesity and diabetes with no effective pharmacotherapies. Growing evidences suggest that several fibroblast growth factors (FGFs) play important roles in diverse aspects of liver pathophysiology. Here we report a previously unappreciated role of FGF4 in the liver. Expression of hepatic FGF4 is inversely associated with NAFLD pathological grades in both human patients and mouse models. Loss of hepatic Fgf4 aggravates hepatic steatosis and liver damage resulted from an obesogenic high-fat diet (HFD). By contrast, pharmacological administration of recombinant FGF4 (rFGF4) mitigates hepatic steatosis, inflammation, liver damage, and fibrogenic markers in mouse livers induced to develop NAFLD and NASH under dietary challenges. Such beneficial effects of FGF4 are mediated predominantly by activating hepatic FGFR4, which activates a downstream Ca2+-CaMKKβ-dependent AMPK-Caspase 6 signal axis, leading to enhanced fatty acid oxidation, reduced hepatocellular apoptosis, and mitigation of liver damage. In conclusion, our study identifies FGF4 as a novel stress-responsive regulator of liver pathophysiology that acts through an FGFR4-AMPK-Caspase 6 signal pathway, shedding lights on novel strategies for treating NAFLD and associated liver pathologies.
gastroenterology & hepatology